Библиографический список

    1. Алгоритмы специализированной помощи больных сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой // Сахарный диабет. –М., 2013. – 6-е изд. 1S. – С. 1-120.

    2. Балаболкин М.И. Профилактика сосудистых осложнений сахарного диабета // Клин. эндокринология. – 2008. – № 2. – С. 23-25.

    3. Варваринский Е.В., Горбенко О.М., Шваюк А.П. и др. Содержание фактора роста эндотелия сосудов и некоторых цитокинов в стекловидном теле пациентов с пролиферативной диабетической ретинопатией // Вестник Оренбургского государственного университета. –2012. – № 12. – С. 26-31.

    4. Глазные проявления диабета / Под ред. Л.И. Балашевича. – СПб., 2004. – 382 с.

    5. Дедов И.И. Диабетическая ретинопатия: современные проблемы // Сахарный диабет. – 2008. – № 3.1. – С. 4-8.

    6. Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция) // Сахарный диабет. – 2010. – № 3 (48). – С. 6-13.

    7. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа» // Сахарный диабет. – 2011. – № 1. – С. 95-105.

    8. Дедов И.И., Шестакова М.В. Сахарный диабет: острые и хронические осложнения. – М.: Медицинское информационное агентство, 2011. – 480 с.

    9. Демидова Т.Ю. Актуальные проблемы оптимизации и индивидуализации управления сахарным диабетом 2 типа // РМЖ. Эндокринология. – 2009. – № 10. – С. 698-702.

    10. Жабоедов Г.Д. Иммунопатологические процессы в сетчатке при развитии диабетической ретинопатии // Вестн. офтальмологии. – 2000. – Т. 116, № 6. – С. 36-39

    11. Жабоедов, Г.Д. Содержание Т-лимфоцитов и экспрессия интрацеллюлярной молекулы адгезии ICAM-1 в сетчатке и хориоидее глаза при диабетической ретинопатии // Вестн. офтальмологии. – 2001. – № 5. – С. 41-42.

    12. Коненков В.И., Климонтов В.В., Шевченко А.В. и др. Комбинации генотипов цитокинов и матриксных металлопротеиназ, ассоциированные с ретинопатией, у женщин с сахарным диабетом 2-го типа // Офтальмохирургия. – 2013. – №4. – С.72-77.

    13. Кочемасова Т.В. Роль межклеточных молекул адгезии 1 и 3 и Е-селектина в развитии ретинопатии у больных сахарным диабетом 1 типа: Дис. … канд. мед. наук. – М., 2002.

    14. Либман Е.С., Шахова Е.В. Слепота и инвалидность вследствие патологии органа зрения в России // Вестн. офтальмологии. – 2006. – № 1. – С. 35-37.

    15. Либман Е.С., Рязанов Д.П., Калеева Э.В. Инвалидность вследствие нарушения зрения в России // Общенациональный офтальмологический форум, 5-й: Сб. науч. тр. / Под ред. В.В. Нероева. – М.: Апрель, 2012. – Т. 2. – С. 797-798.

    16. Липатов Д.В., Александрова В.К., Атарщиков Д.С. и др. Эпидемиология и регистр диабетической ретинопатии в Российской Федерации // Сахарный диабет. – 2014. – № 1. – С. 4-7.

    17. Лихванцева В.Г., Арутюнян Е.В., Белоус О.В. VEGF-зависимая антиангиогенная терапия в офтальмологии // Офтальмология. – 2011. – № 1. – С. 82-87.

    18. Лысенко В.С. Современные представления о патогенезе препролиферативной диабетической ретинопатии // Вестн. Российской академии медицинских наук. – 2003. – № 5. – С.44-47.

    19. Маслова О.В. Оценка эффективности лечебной помощи больным сахарным диабетом по данным скрининга микрососудистых осложнений: Автореф. дис. … канд. мед. наук. – М., 2011. – 26 с.

    20. Метревели Д.С. Распространенность ретинопатии среди больных сахарным диабетом 2-го типа // Проблемы эндокринологии. – 2006. – Т. 52, № 4. – С. 6-8.

    21. Мошетова JI.К., Аржиматова Г. Ш. Современная антиоксидантная терапия диабетической ретинопатии // Клин. офтальмология. – 2006. – Т. 7, № 1. – С. 36-38.

    22. Нероев В.В., Сарыгина О.И., Левкина О.А. Роль сосудистого эндотелиального фактора роста в патогенезе диабетической ретинопатии // Вестн. офтальмологии. – 2009. – № 2. – С. 58-60.

    23. Слепова О.С., Нероев В.В., Илюхин П.А., Сарыгина О.И. Иммунологический контроль при хирургическом лечении больных с пролиферативной диабетической ретинопатией с предварительным интравитреальным введением Луцентиса // Рос. офтальмол. журн. – 2012. – № 1. – С. 69-74.

    24. Сыроедова О.Н., Третьяк Е.Б., Неухаус О.С. Цитокины и их значение в патогенезе диабетической ретинопатии // Проблемы эндокринологии. – 2008. – № 2. – С. 7-14.

    25. Фурсова А.Ж., Пупышева М.М., Филимонов М.Е. и др. Анализ эффективности комплексного лечения диабетической пролиферативной ретинопатии и диабетического макулярного отека // Сибирский науч. мед. журн. – 2015. – Т. 35, № 1. – С. 80-83.

    26. Ходжаев Н.С., Черных В.В., Трунов А.Н. и др. Клинико-лабораторные параллели в оценке эффективности лазерно-медикаментозного лечения диабетического макулярного отека // Офтальмохирургия. – 2008. – № 5. – С. 55-59.

    27. Ходжаев Н.С., Черных В.В., Роменская И.В. и др. Влияние лазерокоагуляции сетчатки на клинико-лабораторные показатели у пациентов с диабетическим макулярным отеком // Вестн. Новосибирского гос. ун-та (Серия: Биология, клиническая медицина). – 2011. – Т. 9, № 4. – С. 48-52.

    28. Черных В.В., Варваринский Е.В., Горбенко О.М. и др. Активность местного воспалительного и пролиферативного процесса в патогенезе диабетической ретинопатии // Бюлл. СО РАМН. – 2013. – Т. 33, № 5. – С. 60-63.

    29. Черных В.В., Трунов А.Н., Варваринский Е.В. и др. Дисбаланс цитокинов и факторов роста в стекловидном теле пациентов с пролиферативной диабетической ретинопатией // Бюлл. СО РАМН. – 2014. – № 3. – С. 61-67.

    30. Черных Д.В., Горбенко О.М., Шваюк А.П. и др. Некоторые факторы роста и цитокины в механизмах развития пролиферативной диабетической ретинопатии // Медицина и образование в Сибири. – 2015. – № 1. – http://www.ngmu.ru/cozo/mos/ article/text_full.php?id=1654.

    31. Шадричев Ф.Е. Диабетическая ретинопатия // Сахарный диабет. – 2008. – № 3. – С. 8-11.

    32. Шестакова М.В. Современный подход к профилактике и лечению диабетической ретинопатии: результаты исследования DIRECT // Справочник поликлинического врача. – 2009. – № 1. – С. 37-39.

    33. Шилова О.Г., Запускалов И.В., Филиппова С.В. Оценка клинической эффективности щадящей и стандартной панретинальной лазеркоагуляции сетчатки при непролиферативной диабетической ретинопатии // Бюллетень сибирской медицины. – 2012. – Т. 11. – № 1. – С. 197-201.

    34. Abdallah W., Fawzi A.A. Anti-VEGF therapy in proliferative diabetic retinopathy // Int. Ophthalmol. Clin. – 2009. – Vol. 49, № 2. – Р. 95-107.

    35. Adamiec-Mroczek J., Oficjalska-Mlynczak J. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes--role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2008. – Vol. 246, № 12. – Р. 1665-1670.

    36. Adamiec-Mroczek J., Oficjalska-Mlynczak J., Misiuk-Hojlo M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples // Cytokine. – 2010. – Vol. 49, № 3. – Р. 269-274.

    37. Kubo Y A.P., Berman A.J. Immunological mechanisms in the pathogenesis of diabetic retinopathy // Semin Immunopathol. – 2008. – Vol. 30, № 2. – P. 65-84.

    38. Afzal N., Zaman S., Shahzad F. et al. Immune mechanisms in type-2 diabetic retinopathy // J. Pak Med. Assoc. – 2015. – Vol. 65, № 2. – P. 159-163.

    39. Amos A.F., McCarty D.J., Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010 // Diabetic Medicine. – 1997. – Vol. 14 (Suppl 5). – P. 1-85.

    40. Arjamaa O., Pollonen M., Kinnunen K. et al. Increased IL-6 levels are not related to NF-κB or HIF-1α transcription factors activity in the vitreous of proliferative diabetic retinopathy // J. Diabetes Complications. – 2011. – Vol. 25, № 6. – P. 393-397.

    41. Behl T., Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy // Pharmacol. Res. – 2015. – Vol. 99, №6. – Р. 137-148.

    42. Bhavsar A.R. Diabetic retinopathy: the latest in current management // Retina. – 2006. – Vol. 26, № 6. – P. 71-79.

    43. Blaslov K., Bulum T., Duvnjak L. Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients // Eur. J. Ophthalmol. – 2015. – Vol. 25, № 4. – Р. 328-332.

    44. Blom M.L., Green W.R., Schachat A.P. Diabetic retinopathy: a review // Md. Med. J. – 1993. – Vol. 42, № 6. – P. 549-556.

    45. Bromberg-White J.L., Glazer L., Downer R. et al. Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous // Invest. Ophthalmol. Vis. Sci. – 2013. – Vol. 54. – P. 6472-6480.

    46. Bosco A., Lerario A.C., Soriano D. et al. Diabetic retinopathy // Arq. Bras. Endocrinol. Metabol. – 2005. – Vol. 49, № 2. – Р. 217-227.

    47. Burdon K.P., Fogarty R.D., Shen W. et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene // Diabetologia. – 2015. – Vol. 58.

    48. Burgos R., Simo R., Audi L. et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy // Diabetologia. – 1997. – Vol. 40, № 9. – Р. 1107-1109.

    49. Canton A., Martinez-Caceres E.M., Hernandez C. et al. CD4-CD8 and CD28 expression in T cells infiltrating the vitreous fluid in patients with proliferative diabetic retinopathy: a flow cytometric analysis // Arch. Ophthalmol. – 2004. – Vol. 122, № 5. – Р. 743-749.

    50. Chen H., Wen F., Zhang X., Su S.B. Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy // Mol. Vis. – 2012. – Vol. 18. – P. 219-226.

    51. Chernykh V., Smirnov E., Varvarinsky Y. et al. IL-4, IL-6, IL-10, IL-17A and vascular endothelial growth factor in the vitreous of patients with proliferative diabetic retinopathy // Advances in Bioscience and Biotechnology. – 2014. – Vol. 5, № 3. – P. 184-187.

    52. Chernykh V.V., Varvarinsky E.V., Smirnov E.V. et al. Proliferative and inflammatory factors in the vitreousof patients with proliferative diabetic retinopathy // Ind. J. Ophthalmology. – 2015. – Vol. 63, № 1. – Р. 19-22.

    53. Cheung C.M., Vania M., Ang M., Chee S.P., Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy // Mol. Vis. – 2012. – Vol. 18. – P. 830-837.

    54. Cheung N., Wong I.Y., Wong T.Y. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications // Diabetes Care. – 2014. – Vol. 37, № 4. – Р. 900-905.

    55. Chibber R., Ben-Mahmud B.M., Chibber S., Kohner E.M. Leukocytesin diabetic retinopathy // Curr. Diabetes. Rev. – 2007. – Vol. 3, № 1. – Р. 3-14.

    56. Cho H., Sobrin L. Genetics of diabetic retinopathy // Curr. Diab. Rep. – 2014. – Vol. 14, № 8. – Р. 515-525.

    57. Citirik M., Kabatas E.U., Batman C. et al. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy // Ophthalmic Res. – 2012. – Vol. 47, № 1. – P. 7-12.

    58. Costagliola C., Romano V., De Tollis M. et al. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy // Mediators Inflamm. – 2013. – Vol. 2013. – P. 629529. – doi: 10.1155/2013/629529. – Epub 2013 Oct 23.

    59. Danis R.P., Ciulla T.A., Criswell M., Pratt L. Anti-angiogenic therapy of proliferative diabetic retinopathy // Expert Opin. Pharmacother. – 2001. – № 3. – Р. 395-407.

    60. Dehghanian F., Hojati Z., Kay M. New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological Process // Avicenna J. Med. Biotechnol. – 2014. – Vol. 6, № 4. – Р. 192-199.

    61. Demircan N., Safran B.G., Soylu M. et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy // Eye. – 2006. – Vol. 20, № 12. – P. 1366-1369.

    62. Ding J., Wong T.Y. Current epidemiology of diabetic retinopathy and diabetic macular edema // Curr. Diab. Rep. – 2012. – Vol. 12. – P. 346-354.

    63. Dong N., Xu B., Wang B., Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy // Mol. Vis. – 2013. – Vol. 19. – P. 1734-1746.

    64. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily // Nat. Rev. Endocrinol. – 2010. – Vol. 6, № 2. – P. 94-101.

    65. Frey T., Antonetti D.A. Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species // Antioxid. Redox. Signal. – 2011. – Vol.15, № 5. – P. 1271-1284.

    66. Fujita T., Hemmi S., Kajiwara M. et al. Complement-mediated chronic inflammation is associated with diabetic microvascular complication // Diabetes Metab. Res. Rev. – 2013. – Vol. 29, № 3. – P. 220-226.

    67. Fulgencio Cunha A.A., Bosco A.A., Veloso C.A. et al. Suppressive effect of aqueous humor from person with type 2 diabetes with or without retinopathy on reactive oxygen species generation // Diabetes Res. Clin. Pract. – 2013. – Vol. 100, № 1. – P. 69-73.

    68. Giet M.V., Henkel C., Schuchardt M., Tolle M. Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects // Curr. Pharm. Des. – 2015. – Vol. 21. – P. 1-9.

    69. Ginter E., Simko V. Type 2 diabetes mellitus, pandemic in 21st century // Adv. Exp. Med. Biol. – 2012. – Vol. 771. – P. 42-50.

    70. Ginter E., Simko V. Global prevalence and future of diabetes mellitus // Adv. Exp. Med. Biol. – 2012. – Vol. 771. – P. 35-41.

    71. Giusti C., Gargiulo P. Advances in biochemical mechanisms of diabetic retinopathy // Eur. Rev. Med. Pharmacol. Sci. – 2007. – Vol. 11, № 3. – Р. 155-163.

    72. Goede V., Brogelli L., Ziche M. et al. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1 // Int. J. Cancer. – 1999. – Vol. 82, № 5. – P. 765-770.

    73. Golias C., Tsoutsi E., Matziridis A. et al. Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease // In Vivo. – 2007. – Vol. 21, № 5. – Р. 757-769.

    74. Gologorsky D., Thanos A., Vavvas D. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy // Mediators Inflamm. – 2012. – Vol. 2012. – P. 629452.

    75. Grassi G. Diabetic retinopathy // Minerva Med. – 2003. – Vol. 94, № 6. – Р. 419-435.

    76. Grigsby J., Betts B., Vidro-Kotchan E. et al. A possible role of acrolein in diabetic retinopathy: involvement of a VEGF/TGFβ signaling pathway of the retinal pigment epithelium in hyperglycemia // Curr. Eye Res. – 2012. – Vol. 37, № 11. – P. 1045-1053.

    77. Guex-Crosier Y., Behar-Cohen F. Diabetic retinopathy: new therapeutic Possibilities // Rev. Med. Suisse. – 2015. – Vol. 11. – P. 101-107.

    78. Gustavsson C., Agardh C.D., Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy // Acta Ophthalmol. – 2013. – Vol. 91, № 5. – P. 445-452.

    79. Gverovic Antunica A., Karaman K., Znaor L. et al. IL-12 concentrations in the aqueous humor and serum of diabetic retinopathy patients // Graefes Arch. Clin. Exp. Ophthalmol. – 2012. – Vol. 250, № 6. – P. 815-821.

    80. Hang H., Yuan S., Yang Q. et al. Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy // Mol. Vis. – 2014. – Vol. 20. – P. 1137-1145.

    81. Hazlett L.D., Jiang X., McClellan S.A. IL-10 function, regulation, and in bacterial keratitis // J. Ocul. Pharmacol. Ther. – 2014. – Vol. 30, № 5. – Р. 373-380.

    82. Heng L.Z., Comyn O., Peto T. et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments // Diabet Med. – 2013. – Vol. 30, № 6. – Р. 640-650.

    83. Hernandez C., Simo R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy // Endocrine. – 2012. – Vol. 41, № 2. – P. 220-226.

    84. Hernandez-Da Mota S.E., Soto-Bahena J.J., Viveros-Sandoval M.E., Cardiel-Rios M. Pro-inflammatory serum cytokines in diabetic retinopathy // Cir. Cir. – 2015. – Vol. 83, № 2. – Р. 100-106.

    85. Horai R., Caspi R. R. Cytokines in autoimmune uveitis // J. Interferon Cytokine Res. – 2011. – Vol. 31, № 10. – P. 734–744.

    86. Hussein K.A., Choksi K., Akeel S. et al. Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy // Exp. Eye Res. – 2014. – Vol. 125. – P. 79-88.

    87. Huang H., Gandhi J.K., Zhong X. et al. TNF-alpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis // Invest. Ophthalmol. Vis. Sci. – 2011. – Vol. 10, № 31. – P. 336-344.

    88. Ireland S.J., Monson N.L., Davis L.S. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10 // Cytokine. – 2015. – Vol. 73, № 2. – Р. 236-244.

    89. Itariu B.K., Stulnig T.M. Autoimmune aspects of type 2 diabetes mellitus – amini-review // Gerontology. – 2014. – Vol. 60, № 3. – Р. 189-196.

    90. Jacot J.L., Sherris D. Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathy // J. Ophthalmol. – 2011. – Vol. 2011. – P. 589813. – doi: 10.1155/2011/589813. – Epub 2011 Oct 30.

    91. Jardeleza M.S., Miller J.W. Review of anti-VEGF therapy in proliferative diabetic retinopathy // Semin. Ophthalmol. – 2009. – Vol. 24, № 2. – Р. 87-92.

    92. Jeon H.J., Choi H.J., Park B.H. et al. Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes // Yonsei Med. J. – 2013. – Vol. 54, № 3. – P. 621-625.

    93. Jiang Y., Liang X., Li X. et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy // Acta Ophthalmol. – 2009. – Vol. 87, № 7. – Р. 736-740.

    94. Johnsen-Soriano S., Sancho-Tello M., Arnal E. et al. IL-2 and IFN-gamma in the retina of diabetic rats // Graefes Arch. Clin. Exp. Ophthalmol. – 2010. – Vol. 248, № 7. – P. 985-990.

    95. Jonas J.B., Jonas R.A., Neumaier M., Findeisen P. Cytokine concentration in aqueous hu-mor of eyes with diabetic macular edema // Retina. – 2012. – Vol. 32, № 10. – P. 2150-2157.

    96. Joussen A.M., Doehmen S., Le M.L. et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations // Mol. Vis. – 2009. – Vol. 15. – P. 1418-1428.

    97. Kajdaniuk D., Marek B., Borgiel-Marek H., Kos-Kudla B. Transforming growth factor β1 (TGFβ1) in physiology and pathology // Endokrynol. Pol. – 2013. – Vol. 64, № 5. – Р. 384-396.

    98. Kanellakis P., Ditiatkovski M., Kostolias G., Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload // Cardiovasc. Res. – 2012. – Vol. 95, № 1. – P. 77-85.

    99. Kaneto H., Katakami N., Matsuhisa M., Matsuoka T.A. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis // Mediators Inflamm. – 2010. – Vol. 2010. – Р. 453892. – doi: 10.1155/2010/453892. –Epub 2010 Feb 16.

    100. Kang M.H., Kim M.K., Lee H.J. et al. Interleukin-17 in various ocular surface inflammatory diseases // J. Korean Med. Sci. – 2011. – Vol. 26, № 7. – P. 938-944.

    101. Kawasaki E. Type 1 diabetes and autoimmunity // Clin. Pediatr. Endocrinol. – 2014. – Vol. 23, № 4. – Р. 99-105.

    102. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy // Exp. Diabetes. Res. – 2007. – Vol. 2007. – Р. 95-103.

    103. Klaassen I., van Geest R.J., Kuiper E.J. et al. The role of CTGF in diabetic retinopathy // Exp. Eye Res. – 2015. – Vol. 133. – P. 37-48.

    104. Klein B.E., Knudtson M.D., Tsai M.Y., Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy // Arch. Ophthalmol. – 2009. – Vol. 127, № 9. – P. 1175-1182.

    105. Kocak N., Alacacioglu I., Kaynak S. et al. Comparison of vitreous and plasma levels of vascular endothelial growth factor, interleukin-6 and hepatocyte growth factor in diabetic and non-diabetic retinal detachment cases // Ann. Ophthalmol. – 2010. – Vol. 42. – P.10-14.

    106. Kollias A.N. Ulbig M.W. Diabetic retinopathy: Early diagnosis and effective treatment // Dtsch. Arztebl. Int. – 2010. – Vol. 107, № 5. – P. 75-83.

    107. Korner F. Diabetic retinopathy-pathophysiological knowledge and modern treatment methods // Ther. Umsch. – 2001. – Vol. 58, № 1. – Р. 41-47.

    108. Koleva-Georgieva D.N., Sivkova N.P., Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy // Folia Med. – 2011. – Vol. 53, № 2. – P. 44-50.

    109. Kroll P., Rodrigues E.B., Hoerle S. Pathogenesis and classification of proliferative diabetic vitreoretinopathy // Ophthalmologica. – 2007. – Vol. 221, №2. – Р. 78-94.

    110. Korthagen N.M., van Bilsen K., Swagemakers S.M. et al. Retinal pigment epithelial cells display specific transcriptional responses upon TNF-α stimulation // Br. J. Ophthalmol. – 2015. – Vol. 99, № 5. – Р. 700-704.

    111. Koskela U.E., Kuusisto S.M., Nissinen A.E. et al. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy // Ophthalmic Res. – 2013. – Vol. 49. – P. 108-114.

    112. Lane M., Mathewson P.A., Sharma H.E. et al. Social deprivation as a risk factor for late presentation of proliferative diabetic retinopathy // Clin. Ophthalmol. – 2015. – Vol. 9. – P. 347-352.

    113. Lange C.A., Stavrakas P., Luhmann U.F. et al. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy // Am. J. Ophthalmol. – 2011. – Vol. 152, № 3. – P. 406-412.

    114. Li S., Fu X.A., Zhou X.F. et al. Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy // Int. J. Ophthalmol. – 2012. – Vol. 5, № 6. – P. 726-730.

    115. Lim A., Stewart J., Chui T.Y. et al. Prevalence and risk factors of diabetic retinopathy in a multi-racial underserved population // Ophthalmic Epidemiol. – 2008. – Vol. 15, № 6. – P. 402-409.

    116. Lim J.W., Han J.R. Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection // Clin. Experiment. Ophthalmol. – 2011. – Vol. 39, № 6. – P. 537-544.

    117. Liu J., Shi B., He S. et al. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy // Mol. Vis. – 2010. – Vol. 16. – P. 2931-2938.

    118. Liu Y., Biarnes Costa M., Gerhardinger C. IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation // PLoS One. – 2012. – Vol. 7, № 5. – Р.36949.

    119. Loukovaara S., Robciuc A., Holopainen J.M. et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy // Acta Ophthalmol. – 2013. – Vol. 91, № 6. – P. 531-539.

    120. Mao C., Yan H. Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy // Indian J. Ophthalmol. – 2014. – Vol. 62, № 6. – P. 699-701.

    121. Matsunaga N., Chikaraishi Y., Izuta H. et al. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy // Ophthalmology. – 2008. – Vol. 115, № 11. – Р. 1916-1922.

    122. Mason J.O. 3rd, Nixon P.A., White M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy // Am. J. Ophthalmol. – 2006. – Vol. 142, № 4. – Р. 685-688.

    123. Matsuoka M., Ogata N., Minamino K., Matsumura M. Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy // Jpn. J. Ophthalmol. – 2006. – Vol. 50, № 2. – P. 116-120.

    124. Matthews D.R., Stratton I.M., Aldington S.J., Holman R.R., Kohner E.M. Risks of progression of retinopathy and vision loss // Arch. Ophthalmol. – 2004. – Vol. 122, № 11. – P. 1631-1640.

    125. McAuley A.K., Sanfilippo P.G., Hewitt A.W. et al. Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis // J. Diabetes Complications. – 2014. – Vol. 28, № 3. – P. 419-425.

    126. Meng N., Zhang Y., Ma J. et al. Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individuals // Eye. – 2015. – Vol. 29, № 2. – Р. 266-271.

    127. Michels R.G. Proliferative diabetic retinopathy: pathophysiology of extraretinal complications and principles of vitreous surgery // Retina. – 1981. – Vol. 1, № 1. – Р. 1-17.

    128. Milne R., Brownstein S. Advanced glycation end products and diabetic Retinopathy // Amino Acids. – 2013. – Vol. 44, № 6. – Р. 1397-1407.

    129. Minnella A.M., Savastano C.M., Ziccardi L. et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy // Acta Ophthalmol. – 2008. – Vol. 86, № 6. – P. 683-687.

    130. Mocan M.C., Kadayifcilar S., Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy // Can. J. Ophthalmol. – 2006. – Vol. 41, № 6. – P. 747-752.

    131. Mohan N., Monickaraj F., Balasubramanyam M. et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy // J. Diabetes Complications. – 2012. – Vol. 26. – P. 435-441.

    132. Muramatsu D., Wakabayashi Y., Usui Y. et al. Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2013. – Vol. 251, № 1. – P. 15-17.

    133. Murata M., Noda K., Fukuhara J. et al. Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy // Invest. Ophthalmol. Vis. Sci. – 2012. – Vol. 53, № 7. – P. 4055-4062.

    134. Murugeswari P., Shukla D., Rajendran A. et al. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease // Retina. – 2008. – Vol. 28, № 6. – P. 817-824.

    135. Mysliwiec M., Balcerska A., Zorena K. et al. The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy // Diabetes Res. Clin. Pract. – 2008. – Vol. 79, № 1. – P. 141-146.

    136. Nadeem A., Javaid K., Sami W. et al. Inverse relationship of serum IL-17 with type-II diabetes retinopathy // Clin. Lab. – 2013. – Vol. 59, № 11-12. – P. 1311-1317.

    137. Nahomi R.B., Palmer A., Green K.M. et al. Pro-inflammatory cytokines downregulate Hsp27 and cause apoptosis of human retinal capillary endothelial cells // Biochim. Biophys. Acta. – 2014. – Vol. 1842, № 2. – P. 164-174.

    138. Nawaz M.I., Van Raemdonck K., Mohammad G. et al. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy // Exp. Eye Res. – 2013. – Vol. 109. – P. 67-76.

    139. Nentwich M.M., Ulbig M.W. Diabetic retinopathy - ocular complications of diabetes mellitus // World J. Diabetes. – 2015. – Vol. 6, № 3. – Р. 489-499.

    140. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer // Cytokine Growth Factor Rev. – 2011. – Vol. 22, № 2. – P. 83-89.

    141. Nicholson B.P., Schachat A.P. A review of clinical trials of anti-VEGF agents for diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2010. – Vol. 248, № 7. – Р. 915-930.

    142. Oh I.K., Kim S.W., Oh J. et al. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy // Curr. Eye Res. – 2010. – Vol. 35, № 12. – P. 1116-1127.

    143. Omar A.F., Silva P.S., Sun J.K. Genetics of diabetic retinopathy // Semin. Ophthalmol. – 2013. – Vol. 28, № 5-6. – Р. 337-346.

    144. Orcutt J., Avakian A., Koepsell T.D. Eye disease in veterans with diabetes // Diabetes Care. – 2004. – Vol. 27, Suppl. 2. – P. 50-53.

    145. Owen L.A., Hartnett M.E. Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema // Curr. Diab. Rep. – 2013. – Vol. 13, № 4. – P. 476-480.

    146. Ozturk B.T., Bozkurt B., Kerimoglu H. et al. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness // Mol. Vis. – 2009. – Vol. 15. – P. 1906-1914.

    147. Paine S.K., Basu A., Mondal L.K. et al. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes // Mol. Vis. – 2012. – Vol. 18. – P. 2749-2757.

    148. Paine S.K., Sen A., Choudhuri S. et al. Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects // Retina. – 2012. – Vol. 32, № 6. – P. 1197-1203.

    149. Palenski T.L., Sorenson C.M., Sheibani N. Inflammatory cytokine-specific alterations in retinal endothelial cell function // Microvasc. Res. – 2013. – Vol. 89. – P. 57-69.

    150. Pascolini D., Mariotti S.P. Global estimates of visual impairment: 2010 // Br. J. Ophthalmol. – 2012. – Vol. 96. – P. 614-618.

    151. Patel J.I., Tombran-Tink J., Hykin P.G. et al. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles // Exp. Eye Res. –2006. – Vol. 82, № 5. – P. 798-806.

    152. Patel J.I., Saleh G.M., Hykin P.G. et al. Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy // Eye. – 2008. – Vol. 22, № 2. – P. 223-228.

    153. Patel S., Chen H., Tinkham N.H., Zhang K. Genetic susceptibility of diabetic retinopathy // Curr. Diab. Rep. – 2008. – Vol. 8, № 4. – P. 257-262.

    154. Pennock S., Kazlauskas A. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses // Mol. Cell Biol. – 2012. – Vol. 32, № 10. – P. 1955-1966.

    155. Petrovic M.G., Korosec P., Kosnik M. et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy // Mol. Vis. – 2008. – Vol. 14. – P. 1382-1387.

    156. Petrovic M.G., Korosec P., Kosnik M., Hawlina M. Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy // Acta Ophthalmol. – 2010. – Vol. 88, № 8. – P. 311-316.

    157. Poniatowski L., Wojdasiewicz P., Gasik R., Szukiewicz D. Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications // Mediators Inflamm. – 2015. – Vol. 2015. – P. 137823. – doi: 10.1155/2015/137823. – Epub 2015 Jan 29.

    158. Postlethwaite A.E., Holness M.A., Katai H., Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4 // J. Clin. Invest. – 1992. – Vol. 90, № 4. – P. 1479-1485.

    159. Pruneau D., Belichard P., Sahel J.A., Combal J.P. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy // Curr. Opin. Invest. Drugs. – 2010. – Vol. 11, № 5. – P. 507-514.

    160. Rangasamy S., McGuire P.G., Das A. Diabetic retinopathy and inflammation: novel therapeutic targets // Middle East Afr. J. Ophthalmol. – 2012. – Vol. 19, № 1. – P. 52-59.

    161. Raymond N.T., Varadhan L., Reynold D.R. et al. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study // Diabetes Care. – 2009. – Vol. 32. – P. 410–415.

    162. Regan D.P., Aarnio M.C., Davis W.S. et al. Characterization of cytokines associated with Th17 cells in the eyes of horses with recurrent uveitis // Vet. Ophtalmol. – 2012. – Vol. 15, № 3. – P. 145-152.

    163. Rema M., Premkumar S., Anitha B. et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I // Invest. Ophthalmol. Vis. Sci. – 2005. – Vol. 46. – P. 2328–2333.

    164. Resnikoff S., Pascolini D., Etya’ale D. et al. Global data on visual impairment in the year 2002 // Bulletin of the World Health Organization. – 2004. – Vol. 82. – P. 844-851.

    165. Rodriguez-Fontal M., Alfaro V., Kerrison J.B., Jablon E.P. Ranibizumab for diabetic retinopathy // Curr. Diabetes Rev. – 2009. – Vol. 5, № 1. – Р. 47-51.

    166. Salam A., Mathew R., Sivaprasad S. Treatment of proliferative diabeticretinopathy with anti-VEGF agents // Acta Ophthalmol. – 2011. – Vol. 89, № 5. – Р. 405-411.

    167. Sadaka A., Giuliari G.P. Proliferative vitreoretinopathy: current and emerging treatments // Clin. Ophthalmol. – 2012. – № 6. – P. 1325-1333.

    168. Saika S., Yamanaka O., Okada Y. et al. TGF beta in fibroproliferative diseases in the eye // Front Biosci. – 2009. – № 1. – Р. 376-390.

    169. Salcedo R., Ponce M.L., Young H.A. et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression // Blood. – 2000. – Vol. 96, № 1. – P. 34-40.

    170. Schoenberger S.D., Kim S.J., Sheng J. et al. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines // Invest. Ophthalmol. Vis. Sci. – 2012. – Vol. 53, № 9. – Р. 5906-5911.

    171. Schwartzman M.L., Iserovich P., Gotlinger K. et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy // Diabetes. – 2010. – Vol. 59, № 7. – P. 1780-1788.

    172. Semeran K., Pawlowski P., Lisowski L. et al. Plasma levels of IL-17, VEGF, and adrenomedullin and S-cone dysfunction of the retina in children and adolescents without signs of retinopathy and with varied duration of diabetes // Mediators Inflamm. – 2013. – Vol. 2013. – P. 274726. – doi: 10.1155/2013/274726. – Epub 2013 Nov 18.

    173. Sesti L.F., Crispim D., Canani L.H. et al. The -308G>a polymorphism of the TNF gene is associated with proliferative diabetic retinopathy in Caucasian Brazilians with type 2 diabetes // Invest. Ophthalmol. Vis. Sci. – 2015. – Vol. 56, № 2. – Р. 1184-1190.

    174. Shen J., Choy D.F., Yoshida T. et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF // J. Cell. Physiol. – 2014. – Vol. 229, № 8. – P. 974-983.

    175. Shimura M., Yasuda K., Nakazawa T. et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2009. – Vol. 247, № 12. – P. 1617-1624.

    176. Schober A. Chemokines in vascular dysfunction and remodeling // Arterioscler. Thromb. Vasc. Biol. – 2008. – Vol. 28, № 11. – Р. 1950-1959.

    177. Simo R., Carrasco E., Garcia-Ramirez M., Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy // Curr. Diabetes Rev. – 2006. – Vol. 2, № 1. – P. 71-98.

    178. Simo R., Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy // Diabetologia. –2008. – Vol. 51, № 9. – Р. 1574-1580.

    179. Sinuani I., Beberashvili I., Averbukh Z., Sandbank J. Role of IL-10 in the progression of kidney disease // World J. Transplant. – 2013. – Vol. 3, № 4. – Р. 91-98.

    180. Smith S.C. Focus on diabetes // Insight. – 2006. – Vol. 31, № 1. – P. 21-22.

    181. Song Q., Zhang Y., Wu Y. et al. Association of erythropoietin gene polymorphisms with retinopathy in a Chinese cohort with type 2 diabetes mellitus // Clin. Experiment. Ophthalmol. – 2015. – Vol. 43, № 6. – Р. 544-549.

    182. Sonoda S., Sakamoto T., Yamashita T. et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema // Retina. – 2014. – Vol. 34, № 4. – P. 741-748.

    183. Spranger J., Pfeiffer A.F. New concepts in pathogenesis and treatment ofdiabetic retinopathy // Exp. Clin. Endocrinol. Diabetes. – 2001. – Vol. 109. – Suppl 2. – Р. 438-450.

    184. Stevens G.A., White R.A., Flaxman S.R. et al. Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990-2010 // Ophthalmology. – 2013. – Vol. 120. – P. 2377-2384.

    185. Striz I., Brabcova E., Kolesar L., Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy // Clin. Sci. – 2014. – Vol. 126, № 9. – Р. 593-612.

    186. Suzuki Y., Nakazawa M., Suzuki K. et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion // Jpn. J. Ophthalmol. – 2011. – Vol. 55. – P. 256-263.

    187. Suzuki Y., Suzuki K., Yokoi Y. et al. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy // Retina. – 2014. – Vol. 34, № 1. – P. 165-171.

    188. Symeonidis C., Papakonstantinou E., Androudi S. et al. Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy // Cytokine. – 2011. – Vol. 54, № 2. – P. 212-217.

    189. Tang J., Kern T.S. Inflammation in diabetic retinopathy // Prog. Retin. Eye Res. – 2011. – Vol. 30, № 5. – P. 343-358.

    190. Tapp R.J., Shaw J.E., Harper C.A. et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population // Diabetes Care. – 2003. – Vol. 26. – P. 1731–1737.

    191. The cytokine: Handbook / Ed. by A. Thompson. – New York: Acad. Press, 1999. – 192 p.

    192. The World Health Report. – 2014. The World Health Statistics report // http://www.who.int/gho/publications/world_health_statistics/2014/en.

    193. Umazume K., Usui Y., Wakabayashi Y. et al. Effects of soluble CD14 and cytokine levels on diabetic macular edema and visual acuity // Retina. – 2013. – Vol. 33, № 5. – P. 1020-1025.

    194. Urbancic M., Kloboves Prevodnik V., Petrovic D. et al. A flow cytometric analysis of vitreous inflammatory cells in patients with proliferative diabetic retinopathy // Biomed. Res. Int. – 2013. – Vol. 2013. – Р. 251528. – doi: 10.1155/2013/251528.

    195. Van Geest R.J., Klaassen I., Vogels I.M., Van Noorden C.J., Schlingemann R.O. Differential TGF-{beta} signaling in retinal vascular cells: a role in diabetic retinopathy? // Invest. Ophthalmol. Vis. Sci. – 2010. – Vol. 51, № 4. – Р. 1857-1865.

    196. WakabayashiY., UsuiY., OkunukiY. et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy // Retina. – 2010. – Vol. 30. – P. 339-344.

    197. Wakabayashi Y., Usui Y., Okunuki Y. et al. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy // Retina. – 2011. – Vol. 31. – P. 1951-1957.

    198. Wakabayashi Y., Usui Y., Okunuki Y. et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy // Invest. Ophthalmol. Vis. Sci. – 2012. – Vol. 53, №10. – P. 6403-6410.

    199. Waisbourd M., Goldstein M., Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs // Acta Ophthalmol. – 2011. – Vol. 89, № 3. – Р. 203-207.

    200. Wang F.H., Liang Y.B., Zhang F. et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study // Ophthalmology. – 2009. – Vol. 116. – P. 461-467.

    201. Wang S., Park J.K., Duh E.J. Novel targets against retinal angiogenesis in diabetic retinopathy // Curr. Diab. Rep. – 2012. – Vol. 12, № 4. – P. 355-363.

    202. Wiedemann P. What is the etiology of diabetic retinopathy? // Ophthalmologe. – 1993. – Vol. 90, № 5. – Р. 426-433.

    203. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 // Diabetes Res. Clin. Pract. – 2011. – Vol. 94, № 3. – Р. 311-321.

    204. Wong T.Y., Cheung N., Tay W.T. et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay EyeStudy // Ophthalmology. – 2008. – Vol. 115. – P. 1869-1875.

    205. Wu Z., MacPhee I.A., Oliveira D.B. Reactive oxygen species in the initiation of IL-4 driven autoimmunity as a potential therapeutic target // Curr. Pharm. Des. – 2004. – Vol. 10, № 8. – Р. 899-913.

    206. Wu W., Tang L. Research progress of anti-angiogenesis drug targets in diabetic retinopathy // Zhonghua Yan Ke Za Zhi. –2014. – Vol. 50, № 11. – Р. 871-876.

    207. Xie X.W., Xu L., Wang Y.X., Jonas J.B. Prevalence and associated factors of diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmology. – 2008. – Vol. 246. – P. 1519-1526.

    208. Yamagishi S., Ueda S., Matsui T. et al. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy // Curr. Pharm. Des. – 2008. – Vol. 14, № 10. – Р. 962-968.

    209. Yang T.T., Song S.J., Xue H.B. et al. Regulatory T cells in the pathogenesis of type 2 diabetes mellitus retinopathy by miR-155 // Eur. Rev. Med. Pharmacol. Sci. – 2015. – Vol. 11. – P. 2010-2015.

    210. Yau J.W., Rogers S.L., Kawasaki R. et al. Global prevalence and major risk factors of diabetic retinopathy // Diabetes Care. – 2012. – Vol. 35. – P. 556-564.

    211. Yoshida Y., Yamagishi S., Matsui T. et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy // Diabetes. Metab. Res. Rev. – 2009. – Vol. 25, № 7. – P. 678-686.

    212. Yoshida S., Ishikawa K., Matsumoto T. et al. Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2010. – Vol. 248, № 6. – P. 799-804.

    213. Yoshida S., Nakama T., Ishikawa K. Antiangiogenic shift in vitreous after vitrectomy in patients with proliferative diabetic retinopathy // Invest. Ophthalmol. Vis. Sci. – 2012. – Vol. 53, № 11. – P. 6997-7003.

    214. YoshidaT., GongJ., XuZ. et al. Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac) // Exp. Eye Res. – 2012. – Vol. 94, № 1. – P. 41-48.

    215. Yoshida S., Kubo Y., Kobayashi Y. et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macularo edema // Br. J. Ophthalmol. – 2015. – Vol. 99, № 7. – Р. 960-966.

    216. Yoshioka K., Yoshida T., Takakura Y. et al. Relationship between polymorphisms 804C/A and 252A/G of lymphotoxin-alpha gene and -308G/A of tumor necrosis factor alpha gene and diabetic retinopathy in Japanese patients with type 2 diabetes mellitus // Metabolism. – 2006. – Vol. 55, № 10. – P. 1406-1410.

    217. You J.J., Yang C.H., Huang J.S. et al. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis // Invest. Ophthalmol. Vis. Sci. – 2007. – Vol. 48, № 11. – P. 5290-5298.

    218. Yu G., Ji X., Jin J., Bu S. Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy // Ann. Clin. Biochem. – 2014. – Vol. 52. – P. 232-236.

    219. Yuuki T., Kanda T., Kimura Y. et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy // J. Diabetes Complications. – 2001. – Vol. 15, № 5. – Р. 257-259.

    220. Zhang J., Hu L.M., Xu G. et al. Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy // Front Biosci. – 2010. – Vol. 2. – P. 912-927.

    221. Zhang X., Saaddine J.B., Chou C.F. et al. Prevalence of diabetic retinopathy in the United States, 2005-2008 // JAMA. – 2010. – Vol. 304, № 6. – P. 649-656.

    222. Zhang X., Yu W., Dong F. Cysteine-rich 61 (CYR61) is up-regulated in proliferative diabetic retinopathy // Graefes Arch. Clin. Exp. Ophthalmol. – 2012. – Vol. 250, № 5. – P. 661-668.

    223. Zhang Y., Meng N., Lv Z. et al. The gene polymorphisms of UCP1 but not PPAR γ and TCF7L2 are associated with diabetic retinopathy in Chinese type 2 diabetes mellitus cases // Acta Ophthalmol. – 2015. – Vol. 93, № 3. – Р. 223-229.

    224. Zhong Y., Li J., Chen Y. et al. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Muller cell-derived inflammatory cytokine production in diabetes // Diabetes. – 2012. – Vol. 61, № 2. – P. 492-504.

    225. Zhou J., Wang S., Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy // Curr. Eye Res. – 2012. – Vol. 37, № 5. – P. 416-420.

    226. Zorena K., Raczynska D., Wisniewski P. et al. Relationship between serum transforming growth factor β 1 concentrations and the duration of type 1 diabetes mellitus in children and adolescents // Mediators Inflamm. – 2013. – Vol. 2013. – P. 849457. – doi: 10.1155/2013/849457. – Epub 2013 Oct 9.